

2nd Global Cell & Gene Therapy Summit


July 07-09, 2025 (Hybrid)

Holiday Inn & Suites - Orlando, FL

SILVER PARTNER



EXHIBIT PARTNER



Welcome to CGT Summit 2025

We are thrilled to extend a warm welcome to all participants of the CGT Summit 2025. This summit will bring together exceptional experts from academia and industry, fostering discussions on diverse topics of cell and gene therapy. CGT Summit's comprehensive agenda will feature talks on topics ranging from genome engineering, gene regulation, and viral vector purification to precision gene therapy, cell therapy innovations, and immunotherapy advances.

CGT sessions also list talks on AI-driven decision-making, efficient process development, compliant manufacturing of iPSC-derived therapies, AAV production optimization, closed and automated manufacturing processes with regulatory considerations, public-private partnerships, clinical trial strategies, and the pivotal journey of scaling cell therapies from trials to commercialization.

With a thematic focus on "From Basic Research to CGT Products: Advancing Cell and Gene Therapies through Innovation, Technology, and Collaboration," the summit aims to have meaningful discussions and impactful networking sessions. We look forward to dynamic discussions, insightful presentations, and collaborative endeavors that will undoubtedly drive progress in the realm of cell and gene therapies.

Contact:

cgt@uniscigroup.org

+1-469-854-2280/81, +1-844-395-4102

Website: <https://cgtsummit.unitedscientificgroup.org/>



EXPERTS @ CGT SUMMIT 2025



Howard Federoff
Chief Medical Officer &
Co-Founder
Kenai Therapeutics, FL



Sebastien Ribault
Chief Commercial Officer
Oxford Biomedica, UK



Arun Srivastava
Professor
University of Florida, FL



Daniel Gibson
Head of Collaborations
**Cell and Gene Therapy
Catapult, UK**



Rajiv Gangurde
Vice President of Technical
Operations for CGT
Parexel, MA



David Margetts
CEO
**BatchLine Co., Ltd.,
Thailand**



Arun Upadhyay
CSO & Head of Research
& Development
Ocugen, PA



Lior Shaltiel
CEO
**NurExone Biologic,
Israel**



Eric Schuur
CEO & Founder
**HepaTx
Corporation, CA**



Courtney Silverthorn
VP, Strategic Alliances and
Innovation
FNIH, MD



Alicia D. Henn
CSO
BioSpherix, Ltd., NY



Alex Blyth
Founder & CEO
Lift Biosciences, UK



Alessandra De Riva
Head of Process
Development and R&D
Advent Bioservices, UK



Mehdi Gasmi
Chief Operating Officer
Sparing Vision, France

Contact:

cgt@uniscigroup.org
+1-469-854-2280/81, +1-844-395-4102
Website: <https://cgtsummit.unitedscientificgroup.org/>

EXPERTS @ CGT SUMMIT 2025



Nathalie Cartier-Lacave
VP Neurobiology, CNS
Sector Lead
Askbio, France



Meg DeAngelis
Endowed Chair & Professor
University at Buffalo,
NY



Neena Haider
Founder
Shifa Precision, MA



Xiaomo Wu
Head of Regenerative
Medicine & Gene Therapy
Dermatology Institute of
Fuzhou, China



Nidhi Kotecha
Program Director,
Regulatory Affairs
Gates Institute, CO



Larry Forman
Founder and CEO
CHO Plus, Inc., CA



Michael Mehler
Director, Cell Therapy
Operations
AstraZeneca, MA



Vaibhav Patel
Director of QARA
University of Minnesota,
MN



Niranjan Kumar
CEO & President
ABSINCGROUP, NJ



Jianxin Hu
Senior Director, Head of
Process and Analytical
Development
Vor Biopharma, MA



Guobao Chen
Principal Research
Scientist
AbbVie, MA



Cassandra Perkins
Director, Value & Access,
Channel, Distribution
Consulting; Cell & Gene
Therapy Consulting
Syneos Health, NC



Susan D'Costa
Chief Technical and
Commercial Officer
Genezen, FL



Carson Dickey
Engineering Manager
Modality Solutions, TX

Contact:

cgt@uniscigroup.org
+1-469-854-2280/81, +1-844-395-4102
Website: <https://cgtsummit.unitedscientificgroup.org/>

EXPERTS @ CGT SUMMIT 2025



Erik Foehr
President
BioTether Sciences Inc.,
CA



Kevin Cast
Partner
Archbow Consulting,
FL



Stefan Sandstrom
Founder and CEO
BioSector Ltd., Japan



Patrick Thiaville
Vice President of
Science and Technology
4basebio, FL



Ajit Magadum
Assistant Professor
University of South
Florida, FL



John Sholar
Chief Executive Officer
jCyte, Inc., CA



**Maryland Rosenfeld
Franklin**
VP & Head of CGT
Labcorp Drug
Development, MI



Timothy Fenn
Vice President
Lexeo Therapeutics, CT



Jason Mercer
Strategic Regulatory
Innovator
Facet Life Sciences, NC

Contact:

cgt@uniscigroup.org
+1-469-854-2280/81, +1-844-395-4102
Website: <https://cgtsummit.unitedscientificgroup.org/>

Program Outline

Day 1, July 07, 2025

Opening Remarks

Genome Engineering, Gene Regulation and Gene Editing Break Throughs

Networking (Coffee) Break

Cell and Gene Therapies for Ocular/Neuro/ Blood Disorders

Cell and Gene Therapies for Rare Diseases

Lunch

Advancements in Cell and Stem Cell-based Therapies

Coffee Break

Gene Therapy: Innovative Platforms, Strategies & Clinical Applications

Precision Gene Therapy for Specific Disorders

***Social & Networking Dinner (Ticket Required)**

Day 2, July 08, 2025

CGT Advances in Cancer: Precision Therapies and Immunomodulation

Networking (Coffee) Break

Viral Vector Innovation and Development

Lunch

Advancing CGT Manufacturing: Optimization, Technologies, and Platforms

Process Development, Manufacturing & Automation

Coffee Break

Optimizing AAV Manufacturing: Engineering, Processing, Analysis and Quality Control

Poster Presentation and Networking Drinks

Day 3, July 09, 2025

Regulatory, Commercialization & Community Engagement

Networking (Coffee) Break

CGT Distribution and Logistics: Optimization, Technologies, and Platforms

Lunch

Panel Discussion I: Next Decade of CGT Research: Future Advancements, Projections, Challenges, and Innovation

Panel Discussion II: Collaborative Approaches: Industry-Academia Partnerships in CGT Manufacturing

Closing Remarks

TENTATIVE

A Unique Immuno-cell Therapy Platform That Can Overcome IO Treatment Resistance

Alex Blyth, Founder & CEO, Lift Biosciences, UK

Nuclease-free Genome Editing with AAV-B19 Hybrid and Chimeric Vectors

Arun Srivastava, George H. Kitzman Professor, University of Florida College of Medicine, FL

Development of Genome-modified NextGen AAV Vectors

Arun Srivastava, George H. Kitzman Professor, University of Florida College of Medicine, FL

mRNA Therapeutics for Cardiovascular Diseases

Ajit Magadum, Assistant Professor, University of South Florida, FL

Emerging Novel Technologies to Enable In vivo Cell Engineering as an Alternative to Traditional Cell Therapies

Guobao Chen, Principal Research Scientist AbbVie, MA

Modifier Gene Therapy Platform for the Treatment of Ocular Diseases

Arun Upadhyay, CSO & Head of Research & Development, Ocugen, PA

A Novel Proteomic Assay for Monitoring Cell Transplantation

Eric Schuur, Chief Executive Officer & Founder, HepaTx, CA

Considerations for Allogeneic Dopaminergic Cell Products for Parkinson's Disease

Howard Federoff, Chief Medical Officer & Co-Founder, Kenai Therapeutics, FL

Pioneering Spinal Cord Injury Treatment: NurExone's Innovative Exosome-based siRNA Therapy with FDA Endorsement and Expanding Pipeline for Neuronal Regeneration

Lior Shaltiel, Chief Executive Officer, NurExone Biologic, Israel

Cell and Gene Therapy Development for Hereditary Connective Tissue Diseases: Overcoming Dominant Negative Phenotype

Erik Foehr, President, BioTether Sciences Inc., CA

Synthetic DNA for Cell & Gene Therapy, and Vaccine Applications

Patrick Thiaville, Vice President of Science and Technology, 4basebio, FL

Day 1 Talks



TBA

Meg DeAngelis, Endowed Chair and Professor, University at Buffalo, NY

TBA

Nathalie Cartier-Lacave, VP Neurobiology, CNS Sector Lead, Askbio, France

TBA

Neena Haider, Founder and CEO, Shifa Precision, MA

More talks will be announced soon.....

From Development to Commercialisation: What is the Key to Success?

Alessandra De Riva, Head of Process Development and R&D, Advent Bioservices, UK

Cycentric Conditions for Decentralized Biomanufacturing

Alicia Henn, CSO, BioSpherix, Ltd., NY

Digital and Automation: Accelerating Innovation in CGT Industrialisation

Daniel Gibson, Head of Collaborations at Cell and Gene Therapy, Catapult, UK

Digitalisation of Cell and Gene Therapies, a Case-study on EBR Deployment for MSC Clinical Trial Production

David Margetts, Chief Executive Officer, BatchLine Co., Ltd., Thailand

Novel Cell Engineering Platform for High-yield AAV Production and Improved Manufacturability

Larry Forman, Founder and CEO, CHO Plus, Inc., CA

The Need for an Unbiased Assay to Detect and Quantify Replication Competent AAV in Clinical Vector Products

Mehdi GASMI, Chief Operating Officer, Sparing Vision, France

Overcoming Analytical Challenges for Characterizing AAV-based Drug Products

Rajiv Gangurde, Vice President of Technical Operations for Cell and Gene Therapy, Parexel, MA

Implementing Phase-appropriate Quality Systems for Cell Therapy: Balancing Flexibility and Compliance

Vaibhav Patel, Director of QARA, University of Minnesota, MN

Viral Vector Innovation: Improving Quality, Productivity, and Gene Size Capacity

Sebastien Ribault, Chief Commercial Officer, Oxford Biomedica, UK

AAV8 Encapsidated HMR-005 Mediates High Efficiency of FVIII-BDD Hepatophilic Transduction and Bleeding Normalization in Hemophilic Mice

Xiaomo Wu, Head of Regenerative Medicine & Gene Therapy, Dermatology Institute of Fuzhou, China

Transformative Advances in Viral Vector Manufacturing: Unlocking Commercial Scalability, Consistency and Cost-effectiveness with Tet-Off PCL Innovation

Susan D'Costa, Chief Technical and Commercial Officer, Genezen, FL

More talks will be announced soon.....

Poster Presentations

Morpholino Based Modification in sgRNA Showed Efficient CRISPR-Cas Gene Editing in HeLa and SH-SY-5Y Cells

Saheli Ganguly, University of Colorado Boulder, CO

Anti-pan AAV - New Versatile Antibody for the Detection of Various AAV Serotypes Including Novel Capsids

Jesse Kay, PROGEN Biotechnik GmbH, Germany

Establishing a Comprehensive Bioanalytical Testing Strategy for Adeno-associated Virus Gene Therapy Clinical Studies

David Colter, Syneos Health, NJ

Scalable and Cost-effective Pluripotent Stem Cell Expansion: Enabling Commercialization

Wonjong Si, Bayer, CA

More talks will be announced soon.....

Optimizing Technology Transfer and Federal Partnerships to Advance Cell and Gene Therapy Innovation

Courtney Silverthorn, Vice President, Strategic Alliances and Innovation, FNIH, MD

Regulatory, Commercialization and Community Engagement for jCell, an Investigational Allogeneic Cell Therapy for Treatment of Retinitis Pigmentosa

John Sholar, Chief Executive Officer, jCyte, Inc., CA

Successful Commercialization Strategies for Cell and Gene Therapy Products in America's Dynamic Market; Lessons Learned from Recent Product Launches

Kevin Cast, Partner, Archbow Consulting, FL

Navigating Regulatory Success in Cell and Gene Therapy Development

Jason Mercer, Strategic Regulatory Innovator, Facet Life Sciences, NC

Community Involvement In Cell And Gene Therapy

Evelyn Harlow, Uganda National Health Laboratory and Diagnostic Services Ministry of Health, Uganda

Panel Discussion I: Breaking Barriers in CG Therapy Manufacturing: Innovations for Scalability and Affordability

Niranjana Kumar, Chief Executive Officer & President, ABSINCGROUP, PA

Larry Forman, Founder and CEO, CHO Plus, Inc., CA

Jianxin Hu, Senior Director, Head of Process and Analytical Development, Vor Biopharma, MA

Nidhi Kotecha, Program Director, Regulatory Affairs, Gates Institute, CO

Alessandra De Riva, Head of Process Development and R&D, Advent Bioservices, UK

Panel Discussion II: Collaborative Approaches: Industry-Academia Partnerships in CGT Manufacturing

More talks will be announced soon.....

Represented by Past Participants



DATAHOW

PROGEN

AMGEN



FNIH

Foundation for the
National Institutes of Health



Applied Cells



TEXAS

The University of Texas at Austin

REGENERON



CUSTOM-BUILT RESEARCH™

MYELOID

Therapeutics, Inc.



ARMATUSBIO



Bristol Myers Squibb®

AXOVIA
THERAPEUTICS



BioSpherix



4basebio



Akribion
Genomics



Gates Institute

UNIVERSITY OF COLORADO
ANSCHUTZ MEDICAL CAMPUS



VirtECS®

ADVANCED PROCESS COMBINATORICS, INC.

MODALIS



Applied StemCell

MAYO
CLINIC



HebeCell

Resolution Therapeutics

Contact:

cgt@uniscigroup.org

+1-469-854-2280/81, +1-844-395-4102

Website: <https://cgtsummit.unitedscientificgroup.org/>



Represented by Past Participants



Contact:
cgt@uniscigroup.org
+1-469-854-2280/81, +1-844-395-4102
Website: <https://cgtsymmit.unitedscientificgroup.org/>



CGT 2024 Attendees Demographic

Seniority Level	Percentage (%)
CEO/President/Co-founder	11.76%
VP/Senior VP	5.88%
Director/Deputy Executive Director	14.71%
Senior Manager	1.96%
Project/Program Manager	1.96%
Professor/Chair	9.80%
Scientist/Senior Scientist	28.43%
Business Development Manager	7.84%
Others	17.65%

Continent	Country	Percentage (%)
North America	USA	82.81%
	UK	5.88%
Europe	Germany	1.96%
	Switzerland	0.98%
	Italy	0.98%
	Israel	1.96%
Asia	China	0.98%
	Taiwan	0.98%
	South Korea	0.98%
	India	0.98%
	Singapore	0.98%
	Hong Kong	0.98%

Contact:

cgt@uniscigroup.org

+1-469-854-2280/81, +1-844-395-4102

Website: <https://cgtsummit.unitedscientificgroup.org/>

Collaborate with CGT Summit 2025



COLLABORATION PROSPECTS

Forge transformative partnerships with leading researchers, biotech companies, and regulatory experts to advance cell and gene therapy innovations, from discovery to commercialization.

INDUSTRY INSIGHTS



Gain crucial insights into the latest advancements in CGT, including gene editing breakthroughs, manufacturing optimization, regulatory strategies, and cutting-edge therapeutic applications.



SHOWCASE OPPORTUNITIES

Highlight your organization's capabilities in CGT by exhibiting groundbreaking technologies, scalable solutions for biomanufacturing, or novel therapeutic platforms to an audience of influential stakeholders.

POST-CONFERENCE RESOURCES



Access exclusive resources, such as case studies on AAV manufacturing, regulatory guidelines for CGT products, and data from clinical trial advancements, to stay ahead in the rapidly evolving CGT landscape.

Contact:

cgt@uniscigroup.org

+1-469-854-2280/81, +1-844-395-4102

Website: <https://cgtsummit.unitedscientificgroup.org/>



Register TODAY!

https://cgtsummit.unitedscientificgroup.org/registration_form

For Sponsorship and Exhibitor Opportunities:

Sponsorship/Exhibitor Guide:

<https://cgtsummit.unitedscientificgroup.org/pdfs/Exhibitor-Guide.pdf>

For more information:

sanvi@cellgenetherapysummit.com

sanvi@cgtsummit.com

+1-469-854-2280/81, +1-844-395-4102

See You @
CGT SUMMIT-2025
Orlando, FL

Contact:

cgt@uniscigroup.org

+1-469-854-2280/81, +1-844-395-4102

Website: <https://cgtsummit.unitedscientificgroup.org/>

